

A microscopic view of numerous white, spherical bacteria, likely cocci, scattered across a vibrant red background. The bacteria vary in size and some appear to be in different stages of division or growth. The overall composition is dense, with a higher concentration of bacteria in the lower-left quadrant.

KARL DRLICA
DAVID S. PERLIN

ANTIBIOTIC RESISTANCE

UNDERSTANDING AND RESPONDING
TO AN **EMERGING
CRISIS**

Antibiotic Resistance

This page intentionally left blank

Antibiotic Resistance

*Understanding and Responding to
an Emerging Crisis*

Karl Drlica
David S. Perlin

Vice President, Publisher: Tim Moore
Associate Publisher and Director of Marketing: Amy Neidlinger
Acquisitions Editor: Kirk Jensen
Editorial Assistant: Pamela Boland
Operations Manager: Gina Kanouse
Senior Marketing Manager: Julie Phifer
Publicity Manager: Laura Czaja
Assistant Marketing Manager: Megan Colvin
Cover Designer: Sheila Schroeder
Managing Editor: Kristy Hart
Project Editor: Anne Goebel
Copy Editor: Apostrophe Editing Services, Inc.
Proofreader: Sheri Cain
Indexer: Erika Millen
Senior Compositor: Gloria Schurick
Manufacturing Buyer: Dan Uhrig

© 2011 by Pearson Education, Inc.
Publishing as FT Press
Upper Saddle River, New Jersey 07458

FT Press offers excellent discounts on this book when ordered in quantity for bulk purchases or special sales. For more information, please contact U.S. Corporate and Government Sales, 1-800-382-3419, corpsales@pearsontechgroup.com. For sales outside the U.S., please contact International Sales at international@pearson.com.

Company and product names mentioned herein are the trademarks or registered trademarks of their respective owners.

All rights reserved. No part of this book may be reproduced, in any form or by any means, without permission in writing from the publisher.

Printed in the United States of America

First Printing January 2011

ISBN-10: 0-13-138773-1

ISBN-13: 978-0-13-138773-7

Pearson Education LTD.

Pearson Education Australia PTY, Limited

Pearson Education Singapore, Pte. Ltd.

Pearson Education Asia, Ltd.

Pearson Education Canada, Ltd.

Pearson Educación de México, S.A. de C.V.

Pearson Education—Japan

Pearson Education Malaysia, Pte. Ltd.

Library of Congress Cataloging-in-Publication Data

Drlica, Karl.

Antibiotic resistance : understanding and responding to an emerging crisis / Karl Drlica, David S. Perlin.
p. ; cm.

Includes bibliographical references and index.

ISBN-13: 978-0-13-138773-7 (hardcover : alk. paper)

ISBN-10: 0-13-138773-1 (hardcover : alk. paper) 1. Drug resistance in microorganisms.

I. Perlin, David. II. Title.

[DNLM: 1. Drug Resistance, Microbial—immunology. 2. Immunity, Innate.

QW 45 D782a 2011]

QR177.D75 2011

616.9'041—dc22

2010014841

We thank our families for their support and dedicate this work to the patients and clinicians who are confronting the harsh reality of drug-resistant infections.

This page intentionally left blank

Contents

	About the Authors	xiii
	Preface	xv
Chapter 1	Introduction to the Resistance Problem	1
	MRSA Is Putting Resistance in the News	1
	Humans Live with Many Pathogens	4
	Antibiotics Block Growth and Kill Pathogens	6
	Broad-Spectrum Antibiotics Also Perturb Our Microbiomes	7
	Antibiotic Resistance Protects Pathogens	8
	Antibiotic Resistance Is Widespread	9
	Antibiotic Resistance Is Divided into Three Types	12
	The Development of New Antibiotics Is Slowing	12
	Vaccines Block Disease	13
	Perspective	14
Chapter 2	Working with Pathogens	17
	Pathogens Are a Diverse Group of Life Forms	17
	Pathogen Numbers Are Measured by Microscopy and by Detecting Growth	18
	Molecular Probes Can Be Specific and Highly Sensitive	23
	Koch's Postulates Help Establish That a Pathogen Causes Disease	24
	Modern Biology Has Refined Koch's Postulates	26
	Pathogen Studies Focus on Populations	28
	Perspective	29
Chapter 3	A Survey of Antibiotics	31
	Antibiotics Are Selective Poisons	31
	Antibiotics Are Found in a Variety of Ways	32
	Antibacterial Agents Usually Attack Specific Targets	37
	Antibacterial Agents May Have a Generalized Effect	40
	Most Antifungal Agents Attack Membranes and Cell Walls	41
	Antiprotozoan Agents Tend to Be Disease-Specific	43

	Antihelminth Agents Are Used with a Variety of Worms	45
	Antiviral Agents Are Often Narrow Spectrum	45
	Human Immunodeficiency Virus (HIV)	46
	Influenza Virus	48
	Herpes Virus	49
	Antibiotic Classes Evolve	50
	Antiseptics and Disinfectants Decontaminate Surfaces	52
	Perspective	53
Chapter 4	Dosing to Cure	55
	Treatment Strategies Have Been Determined Empirically	55
	Susceptibility Testing Guides Antibiotic Choice	57
	Testing for Viruses Bypasses Pathogen Growth	62
	PK/PD Indices Help Determine Antibiotic Dosage	62
	Young Children Are Not Little Adults	65
	Toxic Side Effects Are Determined Empirically	66
	Duration of Treatment Is Determined Empirically	67
	Prophylaxis Preempts Disease	67
	Management Programs Control Hospital Antibiotic Policy	68
	Self-Medication Is Outside the Guidelines	69
	Perspective	70
Chapter 5	Emergence of Resistance	73
	Resistance Can Emerge in Individual Patients	73
	Spontaneous Mutations Are Nucleotide Sequence Changes	74
	Emergence of Spontaneous Resistance Often Arises Stepwise	75
	Mutant Selection Window Hypothesis Describes Emergence of Spontaneous Resistance	77
	Mutations Can Be Caused (Induced) by Antibiotic Treatment	79
	Resistance Arises from Several Molecular Mechanisms	80
	Treatment Time Can Contribute to Resistance	82
	Mutator Mutations Increase Mutation Frequency	83

Phenotypic Resistance Occurs Without Mutations 84
 Resistance May Compromise Antiseptic and
 Disinfectant Use 84
 Viral Resistance Can Arise Readily 84
 Resistance Mutations Can Affect Pathogen Fitness 86
 Unintended Damage Can Arise from Treatment 87
 Perspective 89

Chapter 6 Movement of Resistance Genes Among Pathogens 91

Horizontal Gene Transfer Involves Specific
 Molecular Events 91
 Recombination Involves Breaking and Rejoining of
 DNA Molecules 92
 Plasmids Are Molecular Parasites 94
 Some Plasmids Move by Conjugation 95
 Bacteriophages Move Bacterial Genes by Transduction 96
 Bacterial Transformation Involves Uptake of
 DNA from the Environment 98
 Transposition Moves Genes from One DNA to Another 99
 Gene Mobilization Moves Genes from the
 Chromosome to a Plasmid 99
 Integrons Gather Genes into an Expression Site 101
 Genomic Islands Help Create Pathogens 102
 Plasmid Enzymes Can Be Inhibited 103
 Perspective 103

Chapter 7 Transmission of Resistant Disease 105

Spread of Pathogens Is Highly Evolved 105
 Infection Control as Local Crisis Management 106
 Tuberculosis Is Airborne 107
 Airborne Viruses 114
 Digestive-Tract Pathogens 115
 Direct-Contact Pathogens 116
 Arthropod-Borne Pathogens 118
 Blood-Borne Infections 121
 Multiple-Mode Transmission 121
 Perspective 123

Chapter 8 Surveillance 125

- Surveillance Is the First Line of Defense 125
- The Denominator Effect Lowers Surveillance Accuracy 126
- Surveillance Consortia Collect and Process Data 127
- Molecular Methods Provide Rapid Pathogen Identification 128
- Interpretation of Surveillance Studies 132
- Surveillance Indicates Resistance Problems with Gonorrhea 133
- Policy Changes Are Occurring in Agricultural Practice 133
- Perspective 137

Chapter 9 Making New Antibiotics 139

- New Antibiotics Are Temporary Solutions 139
- Model Systems Are Used to Speed Drug Discovery 140
- Natural Products Are a Source of Antibiotics 141
- High-Throughput Screening Accelerates Antibiotic Discovery 143
- Rational Drug Design Can Identify Antibiotics 144
- New Antibiotics Must Have Few Side Effects 145
- Antibiotic Discovery Faces a Fundamental Economic Problem 146
- Perspective 147

Chapter 10 Restricting Antibiotic Use and Optimizing Dosing 149

- Antibiotic Conservation: Use Less Often When Unnecessary and Higher Amounts When Needed 149
- Human Consumption of Antibiotics Correlates with Resistance 150
- Limiting Human Consumption of Antibiotics 152
- Agricultural Use Contributes to Antibiotic Consumption 155
- Antibiotic Contamination of the Environment Is a Byproduct of Usage 155
- Clinical Resistance and Resistant Mutants Are Not the Same 157

	Dosing to Eradicate Susceptible Cells May Not Halt Emergence of Resistance	158
	Keeping Concentrations Above MPC Restricts Mutant Amplification	159
	Combining MPC with PK/PD Targets	160
	Combination Therapy Restricts Emergence of Resistance	162
	Consideration of Resistance During Drug Discovery	163
	Perspective	164
Chapter 11	Influenza and Antibiotic Resistance	167
	Seasonal Influenza Virus Is Controlled by Vaccines	167
	Antiviral Resistance Has Emerged Among Seasonal Influenza Virus	168
	Pandemic Influenza Can Be a Killer	170
	Avian Flu H5N1 Is a Candidate for Deadly Pandemic Flu	171
	Antibiotics May Play an Important Role in Pandemic Influenza	172
	Antibiotic Resistance Occurs with Avian Flu H5N1	173
	Bacterial Pneumonia May Create Another Resistance Problem	175
	Perspective	176
Chapter 12	Avoiding Resistant Pathogens	177
	Consumer Perspective Differs from That of Public Health Official or Manufacturer	177
	Avoiding Airborne Infection Is Difficult	178
	Precautions Can Be Taken with MRSA	182
	Sexually Transmitted Infections Require Renewed Attention	185
	Arthropod-Borne Infections Are on the Move	186
	Contaminated Food Is Common	188
	Avoid Rounds of Treatment Interspersed with Pathogen Outgrowth	196
	Consume Only with Sound Indications, Choose Optimal Antibiotics	197
	Perspective	199

Afterword	A Course of Action	203
	Overuse	203
	Dosing	204
	Drug Discovery and Surveillance	205
	Resistance as a Side Effect	205
Appendix A	Molecules of Life	207
	The Action of Molecules Defines Life	207
	Proteins Are Molecular Workers	208
	DNA Is the Repository of Genetic Information	209
	RNA Plays Several Roles in Life Processes	215
	Carbohydrates Store Energy, Form Cell Walls, and Make Rigid Structures	218
	Lipids Store Energy and Form Membranes	219
	Cellular Chemistry Is Organized into Metabolic Pathways	220
Appendix B	Microbial Life Forms	221
	Bacteria Lack Nuclei and Other Organelles	221
	Fungi Are Eukaryotes Having Cell Walls But Not Chloroplasts	222
	Parasitic Protozoa Are Eukaryotes Lacking a Cell Wall	223
	Helminths Are Parasitic Worms	224
	Viruses Are Inert Until They Infect	224
	Glossary	227
	Literature Cited	233
	Index	251

About the Authors

Karl Drlica, Ph.D. is a Principal Investigator at the Public Health Research Institute and Professor of Microbiology & Molecular Genetics at the UMDNJ—New Jersey Medical School in Newark, New Jersey. Dr. Drlica’s laboratory focuses on fluoroquinolone action and resistance with *Mycobacterium tuberculosis* and other bacteria, including approaches for slowing the enrichment and amplification of resistant bacterial sub-populations.

David S. Perlin, Ph.D. is Executive Director of the Public Health Research Institute and UMDNJ Regional Biocontainment Laboratory, as well as Professor of Microbiology & Molecular Genetics at the New Jersey Medical School in Newark, New Jersey. He is also a Fellow of the New York Academy of Sciences. Dr. Perlin’s laboratory explores mechanisms of antifungal drug resistance, rapid detection of drug-resistant bloodstream pathogens in high-risk patients, and the application of small-animal models for the study of respiratory pathogens.

This page intentionally left blank

Preface

Recent human activities have profoundly influenced our global environment, often in ways we did not anticipate. An example is our use of antibiotics. Initially hailed as “magic bullets,” these chemical agents are now used so often that success threatens their long-term utility. Unfortunately, the natural mutability of microbes enables pathogens to develop bullet-proof shields that make antibiotic treatments increasingly ineffective. Our failure to adequately address resistance problems may ultimately push the control of infectious disease back to the pre-penicillin era. Indeed, it is now impractical to simply invent additional antibiotics to replace those lost to resistance. However, ideas have emerged for slowing the development of antibiotic resistance in individual patients and in the human population as a whole. *Antibiotic Resistance* introduces these ideas.

Antibiotic Resistance was initially drafted to supplement studies of infectious disease. The problem of resistance tends to be neglected, which puts the well-being of our society at increasing peril. In the course of completing this book, we realized that everyone makes decisions about antibiotic use; therefore, everyone needs to understand how human activities contribute to resistance. Individual patients, medical providers, and agricultural specialists all have a role to play in providing a safer environment. We now aim to make the principles of antibiotic use and effectiveness available to a large audience: farmers, hospital administrators, government regulators, health department personnel, pharmaceutical executives, and especially individual users. (Individual patients pressure their doctors for treatments, and in most cases, patients decide whether to take medicines as prescribed; in countries where prescriptions are not required to purchase antibiotics, patients are major decision makers.) Such diversity in readership poses a challenge.

Fortunately, detailed descriptions of chemical structures, molecular mechanisms, and epidemiological modeling are not required to understand the principles of resistance. We focus on broad concepts supported by examples and descriptions of key experiments. We expect that *Antibiotic Resistance* will be a quick read for persons with knowledge of biology. Those readers can then build on the principles with follow-up reading. Lay readers may find that some terms need to be defined. For them, we have provided a glossary and appendixes covering background concepts.

Our goal with *Antibiotic Resistance* is to point out how human activities contribute to the problem of resistance. Our hope is that an understanding of the complex factors involved in resistance will lead to changes that lengthen antibiotic life spans. An example of the complexity is seen in the traditional practice of setting antibiotic doses only high enough to cure disease. We argue that this practice encourages the emergence of resistance, that more stringent antibiotic regimens are needed to preempt the emergence of resistance. But from an individual patient perspective, using higher doses seems excessive when milder treatment usually cures disease. Why should the individual patient risk toxic side effects to preserve antibiotics for the general population?

Antibiotic waste disposal problems are also complex. In principle, environmental contamination with antibiotics exerts selective pressure on microbes. That pressure can lead to the evolution of resistance genes that then spread from one organism to another and eventually reach human pathogens. We do not know how often this scenario occurs, whether it is reversible, or how much we need to improve agricultural and hospital disposal programs to stop the process.

Fortunately, many resistance issues are not complex. For example, wearing contaminated gloves can spread drug-resistant disease in hospitals: More attention to hand hygiene is required. We are confident that an improved understanding of antibiotic resistance can help preserve these valuable agents.

Each year, thousands of scientific papers are published on antibiotic resistance, making it difficult for even a pair of authors to get everything right. To improve accuracy, we obtained help from David Alland, Vivian Bellofatto, Arnold Bendich, Purnima Bhanot, John Bradley, Dorothy Fallows, Alexander Firsov, Patrick Fitzgerald, Marila Gennaro, Tao Hong, Dairmaid Hughes, Robert Kerns, Barry Kreiswirth, Shajo Kunnath, David Lukac, Simon Lynch, Muhammad Malik, Barun Mathema, Ellen Murphy, Christina Ohnsman, Richard Pine, Lynn Ripley, Snezna Rogelj, Bo Shopsin, Ilene Wagner, Heinz-Georg Wetstein, Xilin Zhao, and Stephen Zinner. We sincerely thank them for their time and for sharing their knowledge.

Chapter 1

Introduction to the Resistance Problem


Summary: As a normal part of life, we are all exposed to pathogens, the tiny microbes and viruses that cause infectious disease. Many pathogen varieties exist. Some are even harmless inhabitants of our bodies most of the time. A common feature of pathogens is their microscopic size. Another is the huge numbers their populations can reach during infection, often in the millions and billions. Human bodies have natural defense systems, but those systems sometimes fail to control infection. For such occasions, pharmaceutical companies have developed antibiotics, chemicals that interfere with specific life processes of pathogens. As a natural response, antibiotic resistance emerges in pathogen populations. Resistance is a condition in which the antibiotic fails to harm the pathogen enough to cure disease. Emergence of resistance often begins with a large pathogen population in which a tiny fraction is naturally resistant to the antibiotic, either through spontaneous changes or through the acquisition of resistance genes from other microbes. Antibiotic treatment kills or halts the growth of the major, susceptible portion of the microbial population. That favors growth of resistant mutants. Prolonged, repeated use of a particular antibiotic leads to the bulk of the pathogen population being composed of resistant cells. Subsequent treatment with that antibiotic does little good. If the resistant organisms spread to other persons, the resulting infections are resistant before treatment: Control of such infection requires a different antibiotic. The development of resistance is accelerated by the mutagenic action of some antibiotics, by the movement of resistance genes from one microbial species to another, and by our excessive, inappropriate use of antibiotics. In the past, a successful medical strategy was to develop new, more potent antibiotics. However, the pharmaceutical pipeline to new antibiotics is no longer adequate.

In this chapter, we define terms and provide an overview of antibiotic resistance. One of the key problems is that as a global community we have not considered antibiotics as a resource to be actively protected.¹ Consequently, we use antibiotics in ways that directly lead to resistance. Changing those ways requires an understanding of antibiotic principles. We begin with a brief description of MRSA to illustrate a bacterial-based health problem.

MRSA Is Putting Resistance in the News

MRSA is the acronym for methicillin-resistant *Staphylococcus aureus*. (Acronyms are usually pronounced letter by letter, as in DNA; scientific names are always italicized; after an initial spelling of the entire name, the first name is often abbreviated by its first letter.) *S. aureus* is a small, sphere-shaped bacterium (see Figure 1-1) that causes skin boils, life-threatening pneumonia, and almost untreatable bone infections. It often spreads by skin-to-skin contact, shared personal items, and shared surfaces, such as locker-room benches. When the microbe encounters a break in the skin, it grows and releases toxins.

Figure 1-1 *Staphylococcus aureus*. Scanning electron micrograph of many MRSA cells at a magnification of 9,560 times.



Public Health Image Library # 7821; photo credit, Janice Haney Carr.

Sixty years ago, *S. aureus* was very susceptible to many antibiotics, including penicillin. Susceptibility disappeared, and the pharmaceutical industry produced increasingly potent antibiotic derivatives. Among these was methicillin, which overcame resistance to penicillin. But in 1960, one year after the introduction of methicillin, MRSA was recovered in the United States. As the resistant bacterium spread through hospitals, surgical procedures and long-term use of catheters became more dangerous. MRSA also caused pneumonia, commonly following influenza, and recently skin infections caused by MRSA captured public attention. In one newspaper account,² pimples on a newborn baby were found to contain MRSA. Antibiotics cleared the infection; however, a month later, the father found boils on his own leg that contained MRSA. Treatment cleared the boils, but they came back. The mother developed mastitis during breast feeding that required a 2-inch incision into her breast to drain the infection. About a year later, an older child developed an MRSA boil on his back. The family is now constantly on alert for MRSA, trying to wash off the bacteria before the microbes find a break in the skin.

Community-associated MRSA has its own acronym (CA-MRSA) to distinguish it from the hospital-associated form (HA-MRSA). Many community-associated *S. aureus* strains are members of a group called USA300, which now accounts for half of the CA-MRSA infections. The strain causes

necrotizing (flesh-eating) skin infection, pneumonia, and muscle infection. In 2005, MRSA accounted for more than 7 million cases of skin and soft tissue infection seen in outpatient departments of U.S. hospitals.³ As expected, CA-MRSA strains are moving into hospitals. In a survey of U.S. hospitals taken from 1999 through 2006, the fraction of *S. aureus* that was resistant to methicillin increased 90%, almost entirely from an influx of CA-MRSA.⁴

Although many infections tend to occur in persons having weakened immune systems, MRSA can infect anyone. For example, healthy young adults tend to be susceptible to a lethal combination of influenza and MRSA pneumonia. In Chapter 7, “Transmission of Resistant Disease,” we describe occurrences of CA-MRSA infection among athletes. Fortunately, most of these dangerous CA-MRSA strains are still susceptible to several antibiotics; however, that susceptibility may soon disappear.

HA-MRSA has been a problem in hospitals for years; in many countries, it is getting worse. For example, in the United States, MRSA climbed from 22% of the *S. aureus* infections in 1995 to 63% in 2007 (from 1999 through 2005, it increased 14% per year).⁵ From 2000 to 2005, MRSA helped double the number of antibiotic-resistant infections in U.S. hospitals, which reached almost a million per year or 2.5% of hospitalizations.⁶ In the United States, more persons now die each year from MRSA (17,000) than from AIDS.

MRSA in hospitals is largely an infection-control problem, that is, control requires keeping the organism from spreading from one patient to another, and if possible, keeping it out of the hospital entirely. Neither is easy. For many years, the Dutch have had an aggressive screening program for incoming patients. They isolate persons who test positive for MRSA and treat them with antibiotics that still work with *S. aureus*. Entire wards of hospitals are closed for cleaning when an MRSA case is found, and colonized healthcare workers are sent home on paid leave until they are cleared of the bacterium. The cost is about half that required to treat MRSA blood-stream infections;⁷ consequently, the effort is thought to be cost-effective.

Until recently, many U.S. hospitals took a different approach: MRSA infections were considered part of the cost of doing business. Holland is a small country that can implement specialized care—the United States has a much higher incidence of MRSA. Nevertheless, in 2007, a Pittsburgh hospital reported that it had adopted the Dutch method. The hospital saved almost \$1 million per year by screening patients and by insisting on more intensive hand-washing protocols for hospital staff.⁸ Other U.S. hospitals are reconsidering their own stance.

Individual consumers will begin to search for hospitals having low MRSA incidence. That search will be easier when hospitals publish their drug-resistant infection statistics. Some states now require reporting of MRSA to health departments; consequently, the numbers are being collected. As an added incentive for MRSA control, some insurance carriers refuse to cover hospital costs when a patient contracts MRSA while there. Hospitals have responded by setting up antibiotic oversight committees to help keep resistance under control.

Humans Live with Many Pathogens

MRSA is one type of pathogen, the collective word applied to microbes and viruses that cause disease. (The term *microbe* includes bacteria, some types of fungi, and protozoans.) Each type of microbe has a distinct lifestyle. Bacteria are single-celled organisms that reproduce by binary fission; each cell grows and then divides to form two new cells. Bacteria cause many of the diseases that make headlines: tuberculosis, flesh-eating disease, and anthrax.

Pathogenic fungi include yeasts and molds. Yeasts are single-celled, whereas molds tend to grow as thread-like structures composed of many cells. (Some pathogenic fungi switch between the forms in response to the environment.) Yeasts and molds cause pneumonia, and in immuno-suppressed persons yeasts and molds can cause deadly systemic infections. Pathogenic protozoans, such as the types that cause malaria, are single-celled microbes that are often spread by insect bites. In tropical and subtropical regions, protozoan diseases are among the major killers of humans. Protozoa and helminths (worms) are usually called parasites rather than pathogens due to their larger size. In *Antibiotic Resistance*, we do not distinguish between pathogens and parasites, because antibiotics are used for maladies caused by parasites as well as by pathogens.

Viruses differ qualitatively from the cellular organisms just mentioned. Viruses cannot reproduce outside a host cell. They require the machinery of a living cell to make new parts. Indeed, one could argue that viruses are not alive even though they are composed of the same types of molecules found in microbes, plants, and animals. Another feature of viruses is that they are generally much smaller than microbes: An electron microscope is required to see most virus particles, whereas a light microscope is adequate for microbes.

Many microbes and viruses are found in and on our bodies (see Box 1-1). Some are beneficial; others are harmful. Some pathogens only occasionally cause infectious symptoms. For example, *Mycobacterium tuberculosis* enters a dormant state in most persons it infects, with a minority of infected persons exhibiting symptoms. However, immune deficiency enables *M. tuberculosis* to exit dormancy and cause disease. Other serious diseases arise from microbes, such as the yeast *Candida albicans*, that ordinarily live harmlessly in or on humans. This organism causes vaginitis with healthy women and more serious disease with immune-compromised patients.

Pathogens that normally grow only inside humans often have effective means of transmission. *Mycobacterium tuberculosis* and influenza virus are two that spread through air; *Vibrio cholerae*, the cause of cholera, contaminates drinking water; and many digestive tract pathogens move with contaminated food. (*Salmonella typhi*, the bacterium that causes typhoid fever, is an example.) Many other pathogens are spread by insects and ticks. Among these are the protozoans responsible for sleeping sickness and malaria, the bacteria that cause plague and typhus, and many types of viruses, such as the agent of yellow fever. Avoiding contact with pathogens is exceedingly difficult.

Box 1-1: Pathogen Diversity

The scientific literature lists about 1,400 species of human pathogen: 538 bacteria, 317 fungi, 287 helminths, 208 viruses, and 57 protozoa. Over the last 20 years, almost 180 species either increased their incidence in humans or are expected to do so shortly. Only a small number, probably fewer than 100, cause disease *only* in humans. Almost 60% of human pathogens are zoonotic, that is, they move between humans and other vertebrates. Most of the others are commensals that usually live in or on humans without harm or are environmental organisms, living in water or soil. As we change our behavior and environment, new diseases emerge, largely through a species-jump from animal to human. Because human societies continue to evolve and change their interactions with animals, we are continually faced with new infectious diseases. For example, changes in food production led to the mad cow disease problem, the exotic pet trade led to monkeypox outbreaks, and harvesting bush meat (monkeys, and so on) probably led to infection with a virus that evolved into human immunodeficiency virus (HIV).^{9,10}

Antibiotics Block Growth and Kill Pathogens

Antibiotics are drugs, taken orally, intermuscularly, or intravenously, that counter an infection. They include agents such as penicillin, tetracycline, ciprofloxacin, and erythromycin. Common bacterial diseases treated with antibiotics are tuberculosis and gonorrhea. Fungal and protozoan diseases are also treatable, but with agents specific for these organisms. (The biochemistry of fungi and protozoa differs substantially from that of bacterial cells.) Antiviral agents constitute a third set of specialized compounds. In general, little cross-reactivity exists among the categories, that is, agents used for fungi do not cure infections caused by viruses, bacteria, or protozoa. However, the principles underlying action and resistance are the same; consequently, in *Antibiotic Resistance* we lump all these agents together as antibiotics. Combining all the agents into a single category risks confusion, because the public has been told repeatedly not to use antibiotics for viral diseases. In this instruction, antibiotics are equated to antibacterials, and indeed antibacterials should not be used for viral infections. But the world is changing. We now have many antiviral and antifungal agents that are just as antibiotic as penicillin. The important issue is to identify principles that enable experimental data obtained with one agent to be used for making decisions with another. Such a cross-disciplinary effort is facilitated by having a general term (antibiotic); we use specific terms, such as antibacterial and antiviral, only when we need to distinguish the agents.

In molecular terms, antibiotics are small molecules that interfere with specific life processes of pathogens. Antibiotics generally enter a pathogen, bind to a specific component, and prevent the component from functioning. In cases of lethal antibacterials, treatment leads to formation of toxic reactive oxygen species that contribute to bacterial death. Not all antibiotics kill pathogens. Indeed, many of the older drugs only stop pathogen growth. Nevertheless, they can be quite effective because they give our natural defense systems time to remove the pathogens.

Antibiotics have been called magic bullets and miracle drugs because they quickly cure diseases that might otherwise cause death. When penicillin first became available in the middle of World War II, it gave life to soldiers who were otherwise doomed by infection of minor wounds. Penicillin was so valuable that urine was collected from treated soldiers and processed to recover the drug. Now antibiotics enable many complicated surgeries to be performed without fear of infection. Developments in molecular biology have even enabled pharmaceutical companies to design antibiotics that work against viruses. Among the more striking examples are antibiotics that attack the human immunodeficiency virus (HIV): They reduce the viral load and relieve many symptoms of HIV disease.

Broad-Spectrum Antibiotics Also Perturb Our Microbiomes

Our bodies contain trillions of bacteria that have evolved to live in humans. More than 38,000 different species live in the human digestive tract, and bacteria occupy at least 20 distinct niches on our skin. The microbes carried by each host are collectively called a microbiome. Humans have evolved to take advantage of the bacteria, and the bacteria gain advantage from us. Box 1-2 describes examples relating to obesity and pain. Some bacteria help humans digest food, whereas others protect from particular pathogens. For example,

Box 1-2: Microbiomes Contribute to Obesity and Pain

Although human digestive tracts contain many different types of bacteria, more than 90% of the total is composed of two general types: the Bacteroidetes and the Firmicutes. These bacteria, along with others, extract energy from foods that would otherwise be indigestible. Obese persons have a higher percentage of Firmicutes in their guts than thin persons, and when obese persons lose weight, the percentage of Bacteroidetes increases. The increased fraction of Bacteroidetes appears to be associated with lower harvest of energy from food.¹¹ A similar difference is observed with genetically obese mice. The obese mice appear to be better able to extract energy from their food, leaving considerably less energy in their feces. When normal, germ-free mice received gut bacteria from obese mice, they put on substantially more body fat than when given bacteria from normal mice, even though food consumption was the same in the two groups. Could gut bacteria contribute to human obesity? Could a shift in microbiome explain why farmers get better growth from cattle fed low levels of antibiotics as “growth promoters”?

Microbiomes may also contribute to sensing some types of pain, as studies with mice indicate. One form derives from inflammation, a complex immune response involving the balance of small molecules called cytokines. Germ-free mice are deficient in the ability to experience a type of inflammatory pain. Introducing bacteria from normal mice into the guts of germ-free animals brought the sensation of pain to normal levels after 3 weeks.¹² Thus, gut bacteria do more than just help mammals digest food.

acid-producing bacteria in the vagina keep yeast populations in check. The complex ecosystem of the digestive tract protects humans from *Clostridium difficile*, the cause of a serious form of diarrhea and bowel inflammation. An unwelcome consequence of antibiotic treatment is the death of much of our microbiome, which can enable resistant pathogen populations to expand.

Antibiotic Resistance Protects Pathogens

Antibiotic resistance is the capability of a *particular* pathogen population to grow in the presence of a *given* antibiotic when the antibiotic is used according to a *specific* regimen. Such a long, detailed definition is important for several reasons. First, pathogens differ in their susceptibility to antibiotics; thus, pathogen species are considered individually. Second, resistance to one antibiotic may not affect susceptibility to another. This means that the antibiotics must also be considered separately. Third, dose is determined as a compromise between effectiveness and toxicity; dose can be changed to be more or less effective and more or less dangerous. Consequently, the definition of resistance must consider the treatment regimen.

Control of infection caused by a resistant pathogen requires higher doses or a different antibiotic. If neither requirement can be met, we have only our immune system for protection from lingering disease or even death. Indeed, infectious diseases were the leading cause of death in developed countries before the discovery of antibiotics. (They still account for one-third of all deaths worldwide.)

Antibiotic resistance is a natural consequence of evolution. Microbes, as is true for all living organisms, use DNA molecules to store genetic information. (Some viruses use RNA rather than DNA; both acronyms are defined in Appendix A, “Molecules of Life.”) Evolution occurs through changes in the information stored in DNA. Those changes are called mutations, and an altered organism is called a mutant. Therefore, an antibiotic-resistant mutant is a cell or virus that has acquired a change in its genetic material that causes loss of susceptibility to a given antibiotic or class of antibiotics.

Antibiotic-resistant pathogens need not arise only from spontaneous mutations—bacteria contain mechanisms for moving large pieces of DNA from one cell to another, even from one species to another. This process, called horizontal gene transfer (see Chapter 6, “Movement of Resistance Genes Among Pathogens”), enables resistance to emerge in our normal bacterial flora and move to pathogens. It is part of the reason that excessive antibiotic use and environmental contamination are so dangerous.

A pathogen is considered to be clinically resistant when an approved antibiotic regimen is unlikely to cure disease. We quantify the level of pathogen susceptibility through a laboratory measure called minimal inhibitory concentration (MIC), which is the drug concentration that blocks growth of a pathogen recovered from a patient. (Pathogen samples taken from patients are called isolates.) A pathogen is deemed resistant if the MIC for the drug exceeds a particular value set by a committee of experts. Clinicians call that MIC value an interpretive breakpoint. Infections caused by pathogen isolates having an MIC below the breakpoint for a particular antibiotic are considered treatable; those with an MIC above the breakpoint are much less likely to respond to therapy. The MIC for a given patient isolate, reported by a clinical microbiology laboratory, helps the physician make decisions about which antibiotic to use. For example, if the isolate is resistant to penicillin but susceptible to fluoroquinolones, the physician may choose to prescribe a member of the latter class.

Resistant microbes can spread from one person to another. Consequently, an antibiotic-resistant infection differs qualitatively from a heart attack or stroke that fails to be cured by medicine: Antibiotic resistance moves beyond the affected patient and gradually renders the drug useless, whereas disseminated resistance does not occur with other drugs. Even resistance to anticancer drugs stays with the patient that developed the resistance because cancer does not spread from one person to another. This distinctive feature of antibiotics means that dosing, suitable effectiveness, and acceptable side effects must be decided by different rules than apply for treatment of noncommunicable diseases. The key concept is that using doses that are just good enough to eliminate symptoms may be fine for diseases such as arthritis, but it is an inadequate strategy for infectious diseases. Nevertheless, that strategy has been the norm ever since antibiotics were discovered.


Antibiotic Resistance Is Widespread

The seriousness of antibiotic resistance depends on perspective. For most diseases, we still have at least one effective drug. If we instantly stopped all resistance from increasing, our healthcare system could continue to perform well. But clinical scientists see resistance increasing and call the situation “dire.”¹³ For some pathogens, such as MRSA and *Acinetobacter*, physicians are forced to turn to antibiotics abandoned decades ago due to their toxic side effects. Our collective task is to develop attitudes and policies that enable all of us to use antibiotics without causing resistance to increase.

We estimate the extent of the resistance problem by surveillance studies. As pointed out, physicians collect microbial samples from patients and send the samples to clinical laboratories for testing (more than 2 billion per year in the United States¹⁴). Pathogens are cultured, and their susceptibility to specific antibiotics is determined (described in Chapter 2, “Working with Pathogens”). Surveillance workers then collect the data and calculate the percentage of the cultures that are resistant. (MIC breakpoints are used as the criterion for resistance.) This percentage, called the prevalence of resistance, indicates whether a particular antibiotic treatment is likely to fail due to pre-existing resistance. Surveillance also reveals trends when samples are obtained over several years from a similar patient population. Seeing the prevalence of resistance increase gives health planners advance warning that a change in treatment regimen is required.

Often, the prevalence of resistance is low for many years, and then it increases rapidly (see Figure 1-2). The challenge is to identify resistance problems while prevalence is still low. Then public health measures, such as increasing dose or halting the spread of the pathogen, may stop the increase. Many examples exist in which local outbreaks of resistance have been controlled. However, on a global level no antibiotic has returned to heavy use when resistance became widespread. Instead, the antibiotic is replaced with a more potent derivative.

Figure 1-2 Change in prevalence of methicillin resistance in *S. aureus* in Great Britain.



Data replotted from Johnson, A.P. “Antibiotic Resistance Among Clinically Important Gram-Positive Bacteria in the UK.” *Journal of Hospital Infection* (1998) 40:17–26.

A partial list of major resistance problems is shown in Box 1-3. This list should be considered as a status report that needs to be continually updated, because pathogens are acquiring resistance to more and more antibiotics. It is also important to point out that resistance is generally a local or regional problem. For example, the prevalence of multidrug resistant (MDR) tuberculosis is particularly high in portions of Eastern Europe and South Africa, but in the United States it is rare.

Box 1-3: Resistance Problems

Several pathogens are close to becoming difficult to treat with antibiotics in some geographic regions. The pathogens and geographic locations listed in Table 1-1 are examples; a comprehensive listing of problem pathogens would require many pages.

Table 1-1 Examples of Pathogens That Have Become Extensively Resistant

Pathogen Species	Disease	Drugs Exhibiting Resistance	Geographical Locations
<i>Acinetobacter baumannii</i>	Pneumonia; wound and urinary infections	All common drugs available; polymyxin is still useful in some localities	Reported worldwide in hospital ICUs ¹⁵ ; pan-resistant in S. Korea, Thailand ^{16,17}
<i>Klebsiella pneumoniae</i>	Pneumonia	Carbapenem, fluoroquinolones, amino glycosides, cephalosporins	Hospitals in many countries, New York City, South Florida ^{18,19}
<i>Mycobacterium tuberculosis</i>	Tuberculosis (XDR-TB)	Rifampicin, isoniazid, fluoroquinolone, second-line injectable (kanamycin, amikacin, capreomycin)	Worldwide, particularly Eastern Europe and South Africa ^{20,21}
<i>Neisseria gonorrhoeae</i>	Gonorrhea	Penicillins, tetracyclines, fluoroquinolones, macrolides, cephalosporins	Western Pacific, Japan ^{22,23,24}
<i>Salmonella enterica</i>	Food-borne bacteremia	Ampicillin, chloramphenicol, tetracycline, sulfamethoxazole, trimethoprim, fluoroquinolones	Worldwide ^{25,26}
<i>Staphylococcus aureus</i>	Many types of infection	β -lactams, fluoroquinolones, gentamycin	Worldwide; examples from European hospitals ^{27,28}

Antibiotic Resistance Is Divided into Three Types

Antibiotic resistance is categorized into several types that require different solutions. One is called acquired resistance. As a natural part of life, mutant cells arise either spontaneously (about one in a million cells per generation) or from the transfer of resistance genes from other microbes (see Chapter 6). When a mutant is less susceptible to a particular antibiotic than its parent, mutant growth is favored during treatment. Eventually, the mutant becomes the dominant member of the pathogen population. One way to slow this process is to limit antibiotic use or use doses that block mutant growth.

When the “acquired” mutant starts to spread from person to person, it causes transmitted or disseminated resistance. In this second type of resistance, the pathogen is already resistant before treatment starts. Disseminated resistance is often highly visible and may elicit immediate action by the healthcare community. Much of that action is aimed at halting transmission.

A third type of resistance involves pathogen species unaffected by particular antibiotics. They are said to be intrinsically resistant. Little can be done about this type of resistance except to develop vaccines and use good infection control practices that keep the pathogens away from us. Most viruses fall in this category.

The Development of New Antibiotics Is Slowing

For many years, pharmaceutical companies developed new antibiotics to replace old ones whose effectiveness was seriously reduced by resistance. The new drugs were often more potent versions of earlier compounds. Unfortunately, finding completely new antibiotic classes becomes progressively more difficult as we exhaust the available drug targets in pathogens. Early in the Twenty-First Century, pharmaceutical companies placed considerable hope on genomic technology as a way to find new bacterial drug targets and thereby new antibiotics. In this approach, computer-based analyses examine the information in bacterial DNA and gene expression profiles to identify potential targets for new antibiotics. So far, that approach has not panned out. At the same time, pharmaceutical executives realized that more money could be made from quality-of-life drugs and drugs for managing chronic diseases. For example, heart disease requires life-long therapy to lower cholesterol. In contrast, antibiotics are administered for only short times. Antibiotics also have a large development cost, almost \$1 billion per drug. As a result, many major pharmaceutical companies shut down their microbiology divisions. Small biotech companies are taking on the effort, but we can no longer depend on new compounds to postpone the antibiotic resistance problem.

Vaccines Block Disease

Vaccines represent an alternative way to combat microbes and viruses. Vaccines are preparations of attenuated pathogen or noninfectious parts of pathogens. When eaten or injected, vaccines create a protective immune response against a particular pathogen. Some vaccines are so effective that they eliminate a disease, as was the case with smallpox. The absence of disease means no resistance problem. Unfortunately, we have been unable to make effective vaccines for many pathogens, most notably HIV, tuberculosis, and malaria. Moreover, pathogen diversity can generate resistance to a vaccine (see Box 1-4).

Box 1-4: Vaccine-Resistant Pathogens

Vaccines typically instruct the human immune system to recognize a pathogen and destroy it. In some circumstances, the pathogen can alter its surface properties to make it less responsive to the immune system. For example, the malaria parasite frequently changes its surface; consequently, the human immune system is always a step behind the parasite. In other cases, the pathogen species exists in many varieties. Shortly after the U.S. anthrax scare of 2001, considerable concern arose because the bacterial strain used in the attacks, the Ames strain, was relatively resistant to the available vaccines.

Vaccines for *Streptococcus pneumoniae* (also known as pneumococcus) illustrate the principle of replacement.²⁹ This organism, which causes pneumonia, otitis media (middle ear infection), sinusitis, and meningitis, colonizes the nasopharynx of 50% of children and about 2.5% of adults. Two types of vaccine are available, one prepared against polysaccharides of 23 pneumococcal strains and the other against a nontoxic diphtheria protein conjugated to polysaccharide from 7 strains of *S. pneumoniae*. The former reduces the impact of disease, whereas the latter also eliminates colonization by the pathogen. Because more than 90 strains (serotypes) of *S. pneumoniae* have been identified, neither vaccine was expected to provide full coverage. Nevertheless, the 7-strain vaccine reduced invasive pneumococcal disease by more than 70%. The fraction of antibiotic-resistant pneumococci also dropped. However, elimination of vaccine strains as colonizers created an ecological niche for nonvaccine strains. As a result, serotype 19A, which was rare before the vaccine became available, replaced vaccine strains. In some cases, capsular switching occurred between a vaccine strain (serotype 4) and a nonvaccine strain (serotype 19A) due to genetic recombination. The resulting strains have virulence properties of serotype 4 with low sensitivity to the vaccine (serotype 19A).

Another serious example concerns the pertussis vaccine. Before vaccination began in the 1940s, pertussis (whooping cough) was a major cause of infant death. In the 1990s, pertussis began a resurgence in countries where most of the population had been vaccinated. Some of the resurgence was due to waning vaccine-induced immunity among the elderly, who increasingly were stricken with whooping cough. However, in Holland between 1989 and 2004, a new strain of *Bordetella pertussis*, the causative agent, replaced the old one among children, and the number of whooping cough cases increased. The new strain appears to be more virulent and produces more toxin than the old one.³⁰

Perspective

Pathogens have attacked humans throughout history. Before the middle of the twentieth century, we relied on our immune systems to survive those attacks. The unlucky and the weak died. Our immune systems were strengthened by improvements in diet, and the frequency of some pathogen attacks was reduced by sanitation and water purification. For other pathogens, vaccines were developed that further decreased the overall burden of infectious disease. Insecticides provided local protection from being bitten by mosquitoes and other disease-carrying vectors. But our fear of pathogens was eliminated only by antibiotics. By taking pills for a few days, we could quickly recover from most bacterial diseases. Resistance is bringing back our fear of the “bugs.”

Many of our resistance problems derive from the cumulative effects of several complex factors. One has been our cavalier attitude. For example, in early 2009, American supermarket chains began to advertise free antibiotics to attract customers. The underlying message was that antibiotics cannot be very valuable and worth protecting. Another factor is lack of stewardship. Drug resistance is discussed widely among health officials, but a coherent plan has not emerged. Hospitals are beginning to oversee their own use, but agricultural and community antibiotic use is largely uncontrolled after the drugs are approved by governmental agencies. For years, medical scientists, notably Fernando Baquero, Stuart Levy, Richard Novick, and Alexander Tomasz, wrote and spoke passionately about the dangers posed by resistance. The medical community now uses education as a strategy to limit antibiotic use. As a part of this effort, the Centers for Disease Control (CDC) formulate and distribute plans for restricting the emergence of resistance in particular environments. In one survey, neonatal intensive care units failed to adhere to the guidelines about 25% of the time.³¹ Outside hospitals individual patients continue to insist on

antibacterial treatments for viral infections, a behavior that stimulates the emergence of resistant bacteria and upsets the balance of microbial ecosystems. In the Latino immigrant community, the prescription process is commonly bypassed.^{32,33} Thus, the educational effort needs to be intensified. A third factor is the philosophy behind the choice of dosage. Doses are kept low enough to cause few side effects but high enough to block susceptible cell growth or kill susceptible cells. Conditions that block the growth of susceptible cells but not that of mutants are precisely those used by microbiologists to enrich mutants. Conventional dosing strategies lead *directly* to the emergence of resistance.

Understanding the factors that drive the emergence and dissemination of antibiotic resistance is central to controlling resistance. In the following chapters, we describe how antibiotics are used, how pathogen populations become resistant, and what we as individuals can do about resistance. We begin by considering aspects of pathogen biology relevant to antibiotic treatment.

This page intentionally left blank

Index

A

- absolute clinical resistance, 157
- Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) properties, 144-145
- accuracy of surveillance, denominator effect and, 126-127
- Acinetobacter baumannii*, 9-11, 205
- acquired resistance, 12
- acyclovir, 36, 49-50
- adamantane resistance, 173-174
- adamantane-resistant avian flu virus H5N1, 173
- adamantanes, 168
- addiction modules, 94-95
- adenosine triphosphate (ATP), 36, 219
- ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties, 144-145
- adverse effects of antibiotics, 200-201
- agar, 19
- agricultural practice
 - antibiotics use in, 38, 155, 203-204
 - removal of fluoroquinolones from U.S. poultry use, 133-134
 - surveillance in, 135
- AIDS, 3, 25-26, 71, 111, 123, 223
- airborne infections
 - avoiding, 178-182
 - disease transmission, 114
- amantadine, 48, 168
- aminoglycosides, 34-37, 65, 101-102, 198
- amphotericin B, 35, 41, 142
- ancient malaria remedies, 44
- The Andromeda Strain* (Crichton), 114
- anthrax outbreak of 2001, 176
- antibacterials, 6. *See also* antibiotics
 - antibacterial classes and resistance mechanisms, 37-40
 - generalized effects of, 40-41
- antibiotic resistance
 - antibiotic resistant mutants, 8
 - definition of, 6-8
 - three types, 12
- antibiotics
 - adamantanes, 168
 - adverse effects of, 200-201
 - antibacterials
 - antibacterial classes and resistance mechanisms, 37-40*
 - generalized effects of, 40-41*
 - antibiotic classes and resistance mechanisms, 34-36
 - antifungal classes and resistance mechanisms, 41-43
 - antihelminth classes and resistance mechanisms, 45
 - antiprotozoan classes and resistance mechanisms, 43-44

- antiviral classes and resistance mechanisms, 45-46
- broad-spectrum antibiotics, 7, 32, 56
- choosing optimal antibiotics, 197-199
- combination therapy, 162-163
- discovering new antibiotics, 12, 31-34
 - computer-assisted drug design, 144-145*
 - consideration of resistance during drug discovery, 163-164*
 - drug safety and side effects, 145-146*
 - economic problems, 146*
 - high-throughput screening, 143-144*
 - model systems for drug research, 140-141*
 - natural sources of antibiotics, 141-142*
 - new antibiotics as temporary solutions, 139*
 - and resistance, 163-164*
- dosages
 - antibiotic concentrations above MPC, 159-160*
 - combination therapy, 162-163*
 - combining MPC with PK/PD targets, 160-161*
 - dosing to eradicate susceptible cells, 158-159*
 - environmental contamination with, 155-157*
- evolution of antibiotic classes, 50-52
- how they work, 6, 31-32
- lethal compounds, 32
- measuring static and lethal action of, 20-21
- molecular mechanism of antibiotic action, 32
 - narrow spectrum, 32
 - neuraminidase inhibitors, 168-169
 - overuse of, 14
 - restricting use of
 - agricultural use, 155*
 - consideration of resistance during drug discovery, 163-164*
 - environmental contamination by antibiotics, 155-157*
 - human consumption, 150-154*
 - overview, 149-150, 164-165*
 - and risk for subsequent resistance, 200
 - sales, 203
 - side effects, 145-146, 200-201
 - specialized (narrow-spectrum) antibiotics, 32
 - static compounds, 31
 - targets, 37-40
 - protein synthesis, 37-38*
 - DNA replication, 38-39*
 - RNA synthesis, 39*
 - cell wall synthesis, 39*
 - folic acid synthesis, 39-40*
- antifungal classes and resistance mechanisms, 41-43**
- antihelminth classes and resistance mechanisms, 45**
- antimalaria drugs, 43-44, 186-187**
- antimicrobial streamlining, 106**
- antimutant strategies for antibiotic development, 164**
- antiprotozoan classes and resistance mechanisms, 43-44**
- antiseptics, 52-53, 80, 84, 88, 101, 182**
- antituberculosis agents, 52, 68, 75, 111-113, 139, 162**

antiviral classes and resistance mechanisms, 45-50

ANZCOSS, 59

artemisinin, 43-44, 187

artesunate, 187

arthropod-borne infections

avoiding, 186-187

disease transmission, 118-120

malaria, 223

ancient malaria remedies, 44

antibiotic-resistant malaria, 118-119

antimalaria drugs, 43

disease transmission, 118-119

risk in travelers, 186-187

-ase suffix, 208

Asian Flu pandemic (1957-1958), 170

***Aspergillus fumigatus*, 21, 131, 157**

atoms, 207-208

ATP (adenosine triphosphate), 219

AUC (area under the PK curve), 63-65, 71, 160

Australian Society for Antimicrobials, 59

autoclaves, 181

avian flu H5N1, 171-174

avoiding resistant pathogens

airborne infections, 178-182

arthropod-borne infections, 186-187

clashes between personal and public health, 177-179

food-borne diseases

Campylobacter, 189, 194-196

disease risks from food-borne pathogens, 188-189

E. coli, 190-194

Salmonella, 190-195

MRSA, 182-184

overview, 177

sexually transmitted infections, 185

avoparcin, 135-136

azidothymidine (AZT), 47

azithromycin, 35, 38, 196

azoles, 35-36, 41-45, 131, 157, 201, 220

AZT (azidothymidine), 47

B

***Bacillus anthracis*, 140**

bacteria

antibacterials, 6. *See also* antibiotics

antibacterial classes and resistance mechanisms, 37-40

generalized effects of, 40-41

biofilms, 29

Bordetella pertussis, 14

Borrelia, 120

Campylobacter, 127, 133-135, 189, 194-196

cellular structure of, 221

Clostridium difficile, 8, 38, 87-89, 123, 200

colonies, 19

counting, 19

culturing, 19-20

defined, 4-5, 17, 221

digestive-tract pathogens, 115-116

direct-contact pathogens, 116

Escherichia coli, 19, 22, 32, 41, 52, 58, 76, 81-82, 88, 96, 100, 122, 127, 135, 140, 156, 188-195, 198-200

Enterococcus, 102, 115, 135-136

explained, 4
 focus on populations, 28-29
 Gram-negative, 18, 34, 37-39, 50, 56, 81, 84, 101, 122
 Gram-positive, 18, 37-39, 50-52, 81, 101
 humans as ecosystems for bacteria, 56
Klebsiella pneumoniae, 11, 81, 97, 101, 121-122
 lawn, 22
Mycobacterium tuberculosis
 completely drug-resistant tuberculosis (CDR-TB), 111
 determining antibiotic resistance by genotyping, 130-131
 disease transmission, 108-113
 dormant state, 5
 extensively resistant (XDR) tuberculosis, 11, 111-113
 in HIV-positive persons, 111
 in homeless populations, 113
 latent tuberculosis, 110
 multi-drug resistant (MDR), 111-112
 testing for exposure to, 109
 treatment of, 110-111
 vaccination against, 109
 persister cells, 28
Pseudomonas aeruginosa, 80, 83
 quorum sensing, 28
 reproduction, 221
 ribosomes, 37-38, 43-45, 215-218
 rickettsia, 119-120
S. aureus, see MRSA
Salmonella, 5, 11, 97, 102, 122, 127, 133, 190-195
 SOS response, 79

Streptococcus pneumoniae, 13, 175
Streptomyces, 39, 81, 141-142, 155
Vibrio cholerae, 5

bacterial pneumonia, 175**bactericidal activity, 20-21, 32****bacteriophages, 96-98, 224**

as therapeutics, 97
 integration, 98
 lysogenic, 98

bacteriostatic activity, 20-21, 31-32***Bacteroides*, 38****Bacteroidetes, 7****Baquero, Fernando, 14** **β -lactamase, 35, 41, 81-84, 99, 122, 163**

inhibitors, 81

 β -lactams, 11, 35, 39-41, 65, 74, 81, 99-102, 155, 159, 163, 175, 184, 198-200**biofilms, 29****bleach, 53****blood-borne pathogens, 121****boil, 2*****Borrelia*, 120****bovine spongiform encephalitis (mad cow disease), 26****breakpoint, 9, 125-126****broad-spectrum antibiotics, 7, 32****buds (yeast), 222****C****CA-MRSA (community-associated MRSA), 2-3, 103, 117, 182, 185*****Campylobacter*, 127, 133-134, 189, 194-196**

- Candida albicans*, 5, 18, 41-42, 154, 222
- carbapenemase, 122
- carbohydrates, 218-219
- Carson, Rachel, 187
- cassette integration, 92
- CC398, 184
- CDC (Centers for Disease Control), 14, 127, 179
- CDR-TB (completely drug-resistant tuberculosis), 111
- Chagas disease, 44
- Chain, Ernst, 34
- children, treatment strategies for, 65-66
- chinchona tree, medicinal properties for malaria, 44
- chloramphenicol, 142
- chloroquine, 43, 118
- Choleraesuis, 195
- choosing optimal antibiotics, 197-199
- ciprofloxacin, 50, 176
- clarithromycin, 38
- clashes between personal and public health, 177-179
- clavulanic acid, 81
- Clinical Laboratory Standards Institute (CLSI), 20, 58
- clinical resistance, 9, 157
- Clostridium difficile*, 38, 87-88
- codons, 210
- cold viruses, 114
- combination therapy, 162-163
- combining MPC with PK/PD targets, 160-161
- commensals, 5, 56-57, 83, 87, 99-100, 131, 155, 164, 189, 193-194
- community-associated MRSA (CA-MRSA), 2-3, 103, 117, 182, 185
- completely drug-resistant tuberculosis (CDR-TB), 111
- complex-17, 136
- Compound 606 (salvorsan), 33
- computer-assisted drug design, 144-145
- conjugation, 91, 95-96, 103
- consumption, 107
- contaminated food
- Campylobacter*, 189, 194-196
 - disease risks from food-borne pathogens, 188-189
 - E. coli*, 190-194
 - Salmonella*, 190-195
- correlation between human consumption of antibiotics and resistance, 150
- counting pathogens, 18-23
- covalent bonds, 207
- Crichton, Michael, 114
- Cryptosporidium*, 44
- culturing bacteria, 19-20
- cytochrome P-450 (CYP450) enzyme system, 65
- cytokines, 7
- ## D
- daptomycin, 35, 39
- DDT, 103, 120, 187
- DEET, 186

Denmark

ban of use of antibiotics as growth promoters, 155

MRSA initiatives, 205

surveillance in food animals, 135

denominator effect and surveillance accuracy, 126-127

deoxyribonucleic acid. See DNA

digestive-tract pathogens, 115-116

digitalis, 142

dihydropteroate synthetase, 39

direct-contact pathogens, 116

directly observed therapy (DOT), 110

disc diffusion, 57-58

discovering new antibiotics

computer-assisted drug design, 144-145

consideration of resistance during drug discovery, 163-164

drug safety and side effects, 145-146

economic problems, 146

high-throughput screening, 143-144

model systems for drug research, 140-141

natural sources of antibiotics, 141-142

new antibiotics as temporary solutions, 139

disease outbreak response. See surveillance

disease transmission. See transmission of resistant disease

disinfectants, 52-53, 80, 84, 121, 194, 199

disseminated resistance, 12

diversity of pathogens, 5, 17-18

DNA (deoxyribonucleic acid)

complementary base pairing, 211

dynamic nature of, 212

explained, 209-213

genomic islands, 102-103

horizontal gene transfer, 8

integrons, 101-102

mimic, 83

nucleic acid probes, 23-24

plasmids, 91, 94

recombination, 92-93

replication, 38

resistance mutations, 157

effect on pathogen fitness, 86

explained, 74-75

fluoroquinolone-resistant gyrase mutants, 82

induced mutations, 79-80

mutant selection window hypothesis, 77-79

mutator mutations and increased mutation frequency, 83

stepwise selection of resistance, 75-76

topoisomerases, 38

transposons, 99

Domagk, Gerhard, 31-34

dosing strategies, 15. See also treatment strategies

antibiotic concentrations above MPC, 159-160

changing dosage levels, 204

combination therapy, 162-163

combining MPC with PK/PD targets, 160-161

determining with PK/PD
(pharmacokinetics/
pharmacodynamics) indices,
62-65

dosing to eradicate susceptible cells,
158-159

**DOT (directly observed therapy),
110**

**drinking water, antibiotic
contamination of, 156**

drug discovery

computer-assisted drug design,
144-145

consideration of resistance during,
163-164

drug safety and side effects, 145-146

economic problems, 146

high-throughput screening, 143-144

model systems for drug research,
140-141

natural sources of antibiotics, 141-142

new antibiotics as temporary
solutions, 139

“druggable” proteins, 145

Duesberg, Peter, 25-26

duration of treatments, 67

E

E-test, 57

***E. coli*, 19, 22, 32, 41, 52, 58, 76, 81-82,
88, 96, 100, 122, 127, 135, 140,
156, 188-195, 198-200**

echinofungins, 42

**economic problems with antibiotic
discovery, 146**

**educating about dangers of antibiotic
overuse, 203**

**efflux pumps, 34-35, 64, 75-76, 80,
198-199, 204, 220**

Ehrlich, Paul, 31-33

electron microscopy, 4, 18

electrons, 207

**EMA (European Medicines
Evaluation Agency), 58**

emergence of resistance

antiseptic and disinfectant use, 84

explained, 73

in individual patients, 73-74, 196-197

molecular mechanisms, 80-82

mutations

effect on pathogen fitness, 86

explained, 74-75

*fluoroquinolone-resistant gyrase
mutants, 82*

induced mutations, 79-80

*mutant selection window
hypothesis, 77-79*

*mutator mutations and increased
mutation frequency, 83*

phenotypic resistance, 84

stepwise selection of resistance, 75-76

treatment time and, 82-83

unintended damage arising from
treatment, 87-88

viral resistance, 84-86

**empiric therapy, 55-56, 60-61, 65-67,
71, 126, 160, 184, 193**

***Enterococcus*, 115**

Enterococcus faecalis, 102

global spread of, 136

vancomycin-resistant *Enterococcus
faecium*, 115

environmental contamination by
antibiotics, 155-157, 204

enzymes, 208

ergosterol, 35, 41-43

erythromycin, 142, 150

ESBLs (extended-spectrum
 β -lactamases), 81, 122

estradiol, 223

ethambutol, 110

EUCAST (European Committee for
Antimicrobial Susceptibility
Testing), 20, 58-59

eukaryotic organisms, 221

European Committee for
Antimicrobial Susceptibility
Testing (EUCAST), 20,
58-59

European Medicines Evaluation
Agency (EMA), 58

evolution

antibiotic resistance as
consequence of, 8

of antibiotic classes, 50-52

extended-spectrum β -lactamases
(ESBLs), 81, 122

extensively resistant (XDR)
tuberculosis, 11, 61, 111-113,
178-179

F

F plasmid, 96

face masks, 180

Falkow, Stanley, 27

Fermicutes, 7

FFP-2 face mask, 180

Fleming, Alexander, 31-33

flexibility of DNA molecules, 212

Florey, Howard, 33

fluconazole, 41

flucytosine, 42

fluoroquinolone-resistant gyrase
mutants, 82

fluoroquinolones, 50, 212. *See also*
quinolones

evolution of, 50-52

fluoroquinolone resistance, 83

fluoroquinolone-resistant gyrase
mutants, 82

removal from U.S. poultry use,
133-135

resistance mechanisms, 38

folate, 40

Food and Drug Administration
(FDA), 40, 66-68, 179

food animals, 89

food-borne disease, avoiding

Campylobacter, 189, 194-196

disease risks from food-borne
pathogens, 188-189

E. coli, 190-194

Salmonella, 190-195

formaldehyde, 53

formularies, 68, 106

foscarnet, 46

France, antibiotic use in, 153

frequency of mutations, 28

fungal diseases, 222-223

fungi

cellular structure of, 222

defined, 4, 17, 222

fungal diseases, 222-223

immune modulators and fungal
infections, 42

molds, 222

Paracoccidioides brasiliensis, 223

structure of, 222

yeasts, 222

G

garenoxacin, 52

gatifloxacin, 52

gemifloxacin, 52

general recombination, 92

**generalized effects of
antibacterials, 40-41**

generalized transduction, 98

genes, 210

gene expression, 216

horizontal gene transfer

addiction modules, 95

cassette integration, 92

conjugation, 91, 95-96

explained, 91-92

gene mobilization, 99

genomic islands, 102-103

integrons, 101-102

plasmids, 94

recombination, 92-93

relaxase, 103

transduction, 91, 96-98

transformation, 98

transposition, 92, 99

vertical transfer, 91

**genetic recombination, 13, 92-93,
96-102, 212**

genomic islands, 102-103

genotyping, 130-131

gentamycin, 38

Germany, antibiotic use in, 153

***Giardia*, 44**

glossary, 227-231

glycosomes, 44

gonorrhea, 11, 52, 133, 185

Gram, Christian, 18

Gram-negative bacteria, 18

Gram-positive bacteria, 18

griseofulvin, 43

**growth promoters, use of
antibiotics as, 7, 38, 86,
135-136, 155, 165, 203**

guinea pig test for tuberculosis, 108

gyrase A protein, 82

H

H1N1 influenza, 169-170

H1N2 influenza, 169

H3N2 influenza, 169

H5N1 avian flu, 171-172

**HA-MRSA (hospital-associated
MRSA), 2-3, 175, 182**

hand hygiene, 123, 181

hand sanitizers, 199

hantavirus pulmonary syndrome, 182

Hata, Sahachiro, 33

helicases, 212

helminths

defined, 4, 17, 224

diseases caused by, 224

herpes virus, 49-50

**high-throughput screening,
143-144**

Hill, Bradford, 27

Hippocrates, 142

HIV (human immunodeficiency virus), 5-6, 13, 24-28, 36, 46-48, 53, 62, 67, 84-86, 108-113, 121, 144, 162-163, 185, 195-197, 224-225

homeless populations, tuberculosis and, 113

homologous recombination, 92

Hong Kong Flu pandemic (1968-1969), 170

horizontal gene transfer, 8

cassette integration, 92

conjugation, 91, 95-96

explained, 91-92

gene mobilization, 99

genomic islands, 102-103

integrons, 101-102

plasmids

addiction modules, 95

explained, 94

recombination, 92-93

relaxase, 103

transduction, 91, 96-98

transformation, 98

transposition, 92, 99

hospital antibiotic policy, 68-69, 106

hospital contact, controlling infections spread by, 123

hospital-associated MRSA (HA-MRSA), 2-3, 182

human consumption of antibiotics

correlation with resistance, 150-152

limiting, 152-154

human immunodeficiency virus (HIV), 25, 46-48, 224

hybridization, nucleic acid, 23-24

hydrocarbon, 219

hydrophobic interactions, 219

hydroxyl radicals, 41

hyphae, 18, 21, 222

I

identifying clinically resistant pathogens, 9

IDSA (Infectious Disease Society of America), 56

immigrant self-medication, 69-70

immune modulators and fungal infections, 42

immunological tests, 62

immune system, 14, 42

immune reconstitution inflammatory syndrome, 67

individual patients, emergence of resistance in, 73-74, 196-197

induced mutations, 79-80

infection control as local crisis management, 3, 106-107

Infectious Disease Society of America (IDSA), 56

influenza

antiviral mechanisms, 168

antiviral resistance, 3, 168-170, 173-175

avian flu H5N1, 171-174

avoiding, 179-181

bacterial pneumonia associated with, 175

membrane protein-2 (M2), 36, 168

overview, 48, 114, 167

pandemic influenza, 170-171

Asian Flu pandemic (1957-1958), 170

- H1N1 pandemic (2009)*, 170
Hong Kong Flu pandemic (1968-1969), 170
potential role of antivirals, 173
public health strategy, 172, 176
Spanish Flu pandemic (1918–1919), 170
 quarantine, 179
 vaccination against seasonal influenza virus, 167-168
 virus types, 168-169
- Inner Canon of the Yellow Emperor**, 142
- integrase inhibitors**, 47
integrons, 36, 101-102, 204-205
interferon- γ release assays, 109
interpretation of surveillance studies, 132
intrinsic resistance, 12
iodine, 53
isolates, 60
isoniazid, 52, 110, 162
- K**
- kanamycin**, 11, 34, 38, 100
kinetoplasts, 44
Klebsiella pneumoniae, 11, 121-122
Koch's postulates, 17, 24-28
- L**
- LD (lethal dose)**, 21
laboratory, biosafety level 3, 23
lead compounds, 143
leishmaniasis, 44
lethal action of antibiotics, measuring, 20-21
lethal compounds, 32
lethal dose (LD), 21
levamisole, 45
levofloxacin, 50-51
Levy, Stuart, 14
LexA, 79
lice, 119-120, 187
light microscopy, 4, 18
lincosamides, 38
linezolid, 34, 37
lipids, 219-220
Listeria, 192
local crisis management, infection control as, 106-107
Lyme disease, 26, 120, 187
lysogenic bacteriophages, 98
lysogeny, 98
- M**
- M. bovis* BCG, 140
M. smegmatis, 140
macrolides, 38, 135, 150, 155-156, 185, 198-200
macromolecules, 208
mad cow disease (bovine spongiform encephalitis), 5, 26
malaria, 4, 53, 223
 ancient malaria remedies, 44
 antibiotic-resistant malaria, 118-119
 antimalaria drugs, 43
 disease transmission, 118-119
 risk in travelers, 186-187
magic bullets, 6
management programs to control hospital antibiotic policy, 68-69

***Materia medica*, 142**

MBC (minimal bactericidal concentration), 21

MDR (multi-drug resistant) tuberculosis, 11, 61, 111-113, 125, 137, 179, 196

measuring

numbers of pathogens, 18-23

static and lethal action of antibiotics, 20-21

mebendazole, 45

membrane protein-2 (M2), 168

messenger RNA (mRNA), 37, 216

metabolic pathways, 220

methicillin, 139

methicillin-resistant *Staphylococcus aureus*. See MRSA

metronidazole, 44

MexAB-OprM, 80

MexCD-OprJ, 80

MexEF-OprN, 80

MexXY-OprM, 80

MfpA, 83

MIC (minimal inhibitory concentration), 9, 20-21, 55-59, 78, 161

MIC creep, 126

microbes, 4

microbiomes, 7

microscopy, 18

minimal bactericidal concentration (MBC), 21

minimal effective concentration, 21

minimal inhibitory concentration. See MIC

model systems for drug research, 140-141

molds

Aspergillus fumigatus, 21, 157

cellular structure of, 222

described, 4, 222

spores, 222

molecular beacons, 129-130

molecular mechanism of antibiotic action, 32

molecular probes, 23-24

molecular resistance mechanisms, 80-82

molecules, 207-208

monkeypox, 5, 26

morphine, 142

mosquitos

transmission of malaria, 118-119

transmission of West Nile Virus, 120

moxifloxacin, 52, 139

MPC (mutant prevention concentration), 77-79, 97, 158, 164

antibiotic concentrations above

MPC, 159-160

combining MPC with PK/PD targets, 160-161

MR2 (membrane protein-2), 168

mRNA (messenger RNA), 37, 216

MRSA (methicillin-resistant *Staphylococcus aureus*), 1-4, 139

avoiding, 182-184

disease transmission, 117

emergence, 74

European MRSA initiatives, 137, 204

and influenza, 175
 susceptibility testing, 60

multi-drug resistant (MDR) tuberculosis, 111-112

multidrug resistant efflux systems, 198

multiple-mode transmission, 121-122

mupirocin, 37

mutant prevention concentration (MPC), 77-78, 160-164

mutant selection window hypothesis, 77-79, 158

mutants, 8

mutations, 8

- effect on pathogen fitness, 86
- explained, 74-75
- fluoroquinolone-resistant gyrase mutants, 82
- frequency of, 28, 75
- induced mutations, 79-80
- mutant selection window hypothesis, 77-79
- mutator mutations and increased mutation frequency, 83
- resistant mutants, 157
- spontaneous mutations, 74-76
- stepwise selection of resistance, 75-76

mutator mutations and increased mutation frequency, 83

***Mycobacterium tuberculosis*, 5, 11**

- antituberculosis agents, 52
- antituberculosis program in Peru, 61-62
- completely drug-resistant tuberculosis (CDR-TB), 111
- determining antibiotic resistance by genotyping, 130-131

- diagnosis by microscopy, 18
- directly observed therapy (DOT), 110
- disease transmission, 108-113
- extensively resistant (XDR) tuberculosis, 111-113, 178
- in HIV-positive persons, 66-67, 111
- in homeless populations, 113
- latent tuberculosis, 110
- model organisms for research, 140
- multi-drug resistant (MDR), 111-112, 137
- prophylactic isoniazid treatment, 68
- slow growth, 60
- testing for exposure to, 109
- transmission of, 107-114, 178
- treatment of, 66-67, 110-111, 139
- vaccination against, 109

N

nalidixic acid, 34, 50

narrow-spectrum antibiotics, 32

National Healthcare Safety Network (NHSN), 128

natural sources of antibiotics, 141-142

***Neisseria gonorrhoeae*, 11, 52, 185**

neomycin, 142

neosalvarsan, 33

neuraminidase inhibitors, 168-169

neuraminidases, 49

new classes of antibiotics, producing, 203

NHSN (National Healthcare Safety Network), 128

nonadherence to therapy, 153

norfloxacin, 50

Novick, Richard, 14

nucleic acid-based diagnosis,
128-131

nucleic acid hybridization, 23-24

nucleic acid probes, 23-24

nucleotides

overview, 209-210

pairing between complementary
nucleotides, 211

sequence, 29

nystatin, 142

O

obesity, microbiomes and, 7

ofloxacin, 50

oseltamivir (Tamiflu), 49,
168-169, 173, 179

outbreaks of resistance, response to.
*See surveillance oversight
committees, 4*

**over-the-counter antifungal
agents, 154**

oxazolidinones, 37

P

pain, microbiomes and, 7

pandemic influenza, 170-171

Asian Flu pandemic (1957-1958),
170

H1N1 pandemic (2009), 170

Hong Kong Flu pandemic
(1968-1969), 170

public health strategy, 172, 176

Spanish Flu pandemic
(1918-1919), 170

***Paracoccidioides brasiliensis*, 223**

parasites, 4, 224

parasitic worms, 224

paromycin, 44

**pathogen fitness, effect of resistance
mutations on, 86**

pathogens. *See also specific pathogens*

arthropod-borne pathogens, 118-120

avoiding

airborne infections, 178-182

arthropod-borne infections,
186-187

*clashes between personal and
public health, 177-179*

food-borne diseases, 188-196

MRSA, 182-184

overview, 177

sexually transmitted infections, 185

bacteria. *See* bacteria

blood-borne pathogens, 121

commensals, 5

defined, 4

detection by nucleic acids, 128-131

digestive-tract pathogens, 115-116

direct-contact pathogens, 116

diversity of, 5, 17-18

establishing causal relationships
with disease

Falkow's corollaries, 27-28

Hill's corollaries, 27

Koch's postulates, 24-26

explained, 4, 17

extensively resistant, 11

focus on populations, 28-29

fungi

cellular structure of, 222

defined, 17, 222

- fungus diseases*, 222-223
- immune modulators and fungal infections*, 42
- molds*, 222
- Paracoccidioides brasiliensis*, 223
- structure of*, 222
- yeasts*, 222
- helminths
 - defined*, 17, 224
 - diseases caused by*, 224
- identifying clinically resistant pathogens, 9
- measuring numbers of, 18-23
- multiple-mode transmission, 121-122
- pathogen diversity, 5
- protozoa
 - defined*, 17, 223
 - diseases caused by*, 4, 223-224
- transmission of, 5
- vaccine-resistant pathogens, 13
- viruses. *See* viruses
- zoonotic pathogens, 5
- PCR (polymerase chain reaction)**, 213-215
- penicillin**, 6, 31-33, 151-152
- pentamidine**, 44
- persists**, 28
- personal health, clashes with public health**, 177-179
- pertussis (whooping cough)**, 14
- Peru, antituberculosis program in**, 61-62
- pharmacodynamics**, 62-65
- pharmacokinetics**, 55, 62-65
 - pharmacokinetic mismatch and resistance, 162
- phenotypic resistance**, 84
- phosphonates**, 103
- pigs, MRSA in**, 184
- PK/PD (pharmacokinetics/ pharmacodynamics) indices**, 62-65, 71
 - combining MPC with PK/PD targets, 160-161
- plague**, 5
- plasmids**, 91, 94
- Plasmodium falciparum*, 118
- Plasmodium knowlesi*, 118
- Plasmodium malariae*, 118
- Plasmodium ovale*, 118
- Plasmodium vivax*, 118
- pneumonia, 1-3, 11**
 - bacterial pneumonia, 175
 - see Klebsiella and Streptococcus pneumoniae*
- polymerase**, 211
 - polymerase chain reaction (PCR), 213-215
 - polymerase inhibitors, 47
- polymers**, 208
- populations, focus on**, 28-29
- poultry, removal of fluoroquinolones from**, 133-134
- prescriptions**, 89
- prevalence of antibiotic resistance**, 9-11, 125
- prokaryotic organisms**, 221
- Prontosil Red**, 34
- prophylaxis**, 67-68
- protective clothing, virus transfer from**, 181

**protein synthesis, antibacterial
action on, 37**

proteins

- gyrase A, 82
- LexA, 79
- MfpA, 83
- overview, 208-209
- repressors, 216

protozoa

- defined, 17, 223
- diseases caused by, 4, 223-224

***Pseudomonas aeruginosa*, 52, 80, 83,
122-123, 197-198**

**public health, clashes with personal
health, 177-179**

puromycin, 142

pyrazinamide, 110

pyrethrum, 187

Q

quarantine for influenza, 179

**quaternary ammonium
compounds, 53**

quinacrine, 43

quinine, 43-44

**quinolone (fluoroquinolone), 34,
38-41, 50-52, 82, 100, 134,
139, 159-160, 175**

quorum sensing, 28-29

R

reactive oxygen species, 40-41

recombination, 92-93

relaxase, 103

repressors, 216

reproduction

of bacteria, 221

of yeasts, 222

research, importance of, 205

resistance

antiseptic and disinfectant use, 84

in commensals, 100

and consumption, 150-155

emerging in individuals, 73-74,
196-197

explained, 73

horizontal gene transfer

addiction modules, 95

cassette integration, 92

conjugation, 91, 95-96

explained, 91-92

gene mobilization, 99

genomic islands, 102-103

integrons, 101-102

plasmids, 94

recombination, 92-93

relaxase, 103

transduction, 91, 96-98

transformation, 98

transposition, 92, 99

molecular mechanisms, 80-82

mutations

effect on pathogen fitness, 86

explained, 74-75

*fluoroquinolone-resistant gyrase
mutants, 82*

induced mutations, 79-80

*mutant selection window
hypothesis, 77-79*

mutator mutations and increased mutation frequency, 83

pathogen fitness, 86

perspective, 177-178

phenotypic resistance, 84

problems, 11, 14-15

stepwise selection of, 75-76

treatment time and, 82-83

unintended damage arising from treatment, 87-88

viral resistance, 84-86

resistant disease transmission.

See transmission of resistant disease

resistant pathogens, avoiding

airborne infections, 178-182

arthropod-borne infections, 186-187

clashes between personal and public health, 177-179

food-borne diseases, 188-196

MRSA, 182-184

overview, 177

sexually transmitted infections, 185

response to disease outbreaks.

See surveillance

restricting antibiotic use. *See also dosing strategies*

agricultural use, 155

consideration of resistance during drug discovery, 163-164

environmental contamination by antibiotics, 155-157

human consumption

correlation between human consumption of antibiotics and resistance, 150-152

limiting, 152-154

overview, 149-150, 164-165

ribavirin, 46

ribonucleic acid. *See* RNA

ribosomes, 37-38, 43-45, 215-218

ricin, 37

rickettsia, 119-120

rifampicin, 39, 52, 110, 162, 216

rifamycin, 142

rimantadine, 168

RNA (ribonucleic acid)

mRNA, 37

overview, 215-218

rRNA, 37

tRNA, 37

Russia, training TB workers in, 112

S

***S. aureus*, 1-4, 116-117, 139, 158-159, 175. *See also* MRSA**

salicylic acid, 142

***Salmonella*, 5, 11, 97, 102, 122, 127, 133, 141, 188-195**

salvorsan, 33

SARS (severe acute respiratory syndrome), 114-115, 181

seasonal influenza virus

antiviral resistance to, 168-170

vaccination against, 167-168

self-medication, 69-70, 154, 197

serotype, 13

severe acute respiratory syndrome (SARS), 114-115, 181

sexually transmitted infections, avoiding, 185

***Shigella*, 192**

sickle cell disease, 224

sickle-cell trait, 223

side effects of antibiotics, 66-67,
145-146, 200-201

Silent Spring (Carson), 187

site-specific recombination, 92

sleeping sickness, 44

solutions for antibiotic resistance

drug discovery process, 204

education, 203

European MRSA initiatives, 204

higher dosage levels, 204

limited agricultural use of
antibiotics, 203

lower environmental levels of
antibiotics, 204

new classes of antibiotics, 203

research, 205

SOS response, 79

Spanish Flu pandemic
(1918-1919), 170

Speaker, Andrew, 178

specialized transduction, 98

spontaneous mutations, 74-75

spores, 17, 222

Staphylococcus aureus. See *S. aureus*
and MRSA

static action of antibiotics,
measuring, 20-21

static compounds, 31

stepwise selection of resistance, 75-76

Sterling Drug Company, 34

Strategic National Stockpile, 172

Streptococcus pneumoniae, 13, 39,
50-52, 76, 159, 164, 177, 180,
201

Streptomyces, 39, 81, 141-142

Streptomyces aureofaciens, 155

streptomycin, 38, 142

sugars, 218-219

sulbactam, 81

sulfa drugs (sulfonamides), 31, 34,
39-40

surgical masks, 180

surveillance

denominator effect and surveillance
accuracy, 126-127

explained, 10, 125

as first line of defense, 125-126

genotyping, 130-131

groups performing surveillance, 127

importance of, 137

interpretation of surveillance
studies, 132

nucleic acid-based diagnosis,
128-131

and removal of fluoroquinolones from
U.S. poultry use, 133-134

and studies of resistance problems
with gonorrhea, 133

surveillance in Danish food
animals, 135

surveillance networks for antibiotic
resistance, 127-128

susceptibility testing, 57-60

syncytia, 23

T

Tamiflu (oseltamivir), 49, 168-169,
173, 179

tazobactam, 81

TEM enzyme, 81

testing

- for *M. tuberculosis* exposure, 109
- immunological/biological testing, 62
- susceptibility testing, 57-60

tetracycline, 38, 142

Theory of Febrile Diseases and Synopsis of the Golden Cabinet (Zhang), 142

ticks, and spread of Lyme disease, 120**tobramycin, 38****tolnaftate, 43****Tomasz, Alexander, 14****topoisomerases, 38, 212****toxic side effects, determining, 66-67, 200****transduction, 91, 96-98****transfer RNA (tRNA), 216-217****transformation, 91, 98****transmission of resistant disease, 5, 105-124**

- airborne viruses, 114
- arthropod-borne pathogens, 118-120
- blood-borne pathogens, 121
- controlling infections spread by contact in hospitals, 123
- digestive-tract pathogens, 115-116
- direct-contact pathogens, 116
- explained, 105
- infection control as local crisis management, 106-107
- MRSA, 117
- multiple-mode transmission, 121-122
- tuberculosis, 108-113
- virus transfer from protective clothing, 181

transposition, 92, 99**transposons, 92, 99-101**

Treatise on Differentiation and Treatment of Seasonal Febrile Diseases (Wu), 142

treatment strategies

- children, 65-66
- dosing strategies, 15
 - antibiotic concentrations above MPC, 159-160*
 - changing dosage levels, 204*
 - combination therapy, 162-163*
 - combining MPC with PK/PD targets, 160-161*
 - determining with PK/PD (pharmacokinetics/pharmacodynamics) indices, 62-65*
 - dosing to eradicate susceptible cells, 158-159*
- duration of treatment, 67
- empiric therapy, 55-56
- immunological/biological testing, 62
- management programs to control hospital antibiotic policy, 68-69
- overview, 55, 70-71
- PK/PD (pharmacokinetics/pharmacodynamics) indices, 62-65
- prophylaxis, 67-68
- risk for subsequent resistance, 200
- self-medication, 69-70
- susceptibility testing, 57, 59-60
- toxic side effects, determining, 66-67
- tuberculosis, 110-111
- unintended damage arising from treatment, 87-88

treatment time and emergence of resistance, 82-83

Treponema pallidum, 33

triazoles, 41

trichlosan, 199

tRNA (transfer RNA), 37,
216-217

trovafloxacin, 50

trypanosomes, 44

tuberculosis, 5, 11

antituberculosis agents, 52

antituberculosis program in Peru,
61-62

completely drug-resistant tuberculosis
(CDR-TB), 111

control program in Peru, 60-62

determining antibiotic resistance by
genotyping, 130-131

disease transmission, 108-113

extensively resistant (XDR)
tuberculosis, 111, 113

in HIV-positive persons, 111

in homeless populations, 113

latent tuberculosis, 110

model organisms for research,
140

multi-drug resistant (MDR), 11,
111-112

prophylactic isoniazid treatment, 68

testing for exposure to, 109

transmission of, 107-114, 178

treatment of, 110-111

vaccination against, 109

types of antibiotic resistance, 12

typhoid, 5

typhus, 5, 103, 119

U

**U.S. poultry, removal of
fluoroquinolones from,
133-134**

USA-300, 2

**unintended damage arising from
treatment, 87-88**

V

vaccines

explained, 13

against seasonal influenza virus,
167-168

against tuberculosis, 109

reducing fear of pathogens, 53

vaccine-resistant pathogens, 13

vaginal yeast infections, 154

valley fever, 223

vancomycin, 39, 142

**vancomycin-resistant *Enterococcus
faecium*, 115**

**vancomycin-resistant enterococci
(VRE), 115-116, 135-136**

viral focus, 23

viral resistance, 84-86

viral plaques, 22

viruses

airborne viruses, 114

antiviral classes and resistance
mechanisms, 45-46

bacteriophage, 22

cellular structure of, 224

defined, 4, 17, 224

detecting viral antibiotic resistance,
174-175

herpes virus, 49-50

HIV (human immunodeficiency virus), 25, 46-48, 85-86, 224

influenza

- antiviral resistance to seasonal influenza, 168-170*
- avian flu H5N1, 171-174*
- avoiding, 179-180*
- bacterial pneumonia associated with, 175*
- membrane protein-2 (M2), 168*
- overview, 48, 114, 167*
- pandemic influenza, 170-172, 176*
- quarantine, 179*
- vaccination against seasonal influenza virus, 167-168*

life cycle, 224

SARS (severe acute respiratory syndrome), 114, 181

virus transfer from protective clothing, 181

West Nile Virus, 120

VITEK, 59

VRE (vancomycin-resistant enterococci), 135-136

W

water, antibiotic contamination of, 156

West Nile Virus, 120, 187

whooping cough, 14

widespread nature of antibiotic resistance, 9-11

World Health Organization, 127

worms (parasitic), 224

Wu Jutong, 142

X

X-ray crystallography, 144

XDR (extensively resistant) tuberculosis, 111-113

Y

yeasts, 17

Candida albicans, 154

defined, 4, 222

reproduction, 222

yellow fever, 5, 53, 118-120

Z

zanamivir, 168

Zhang Zhongjing, 142

zoonotic pathogens, 5